



ECIBC recommendation on staging breast cancer with PET-CT at clinical stage I

Bibliography

Evidence of effects

Hogan MP, Goldman DA, Dashevsky B, Riedl CC, Gonen M, Osborne JR, et al. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma. J Nucl Med. 2015 Nov;56(11):1674-80

Lebon V, Alberini JL, Pierga, JY, Dieras V, Jehanno N, Wartski M. Rate of Distant Metastases on 18F-FDG PET/CT at Initial Staging of Breast Cancer: Comparison of Women Younger and Older Than 40 Years. J Nucl Med. 2017 Feb;58(2):252-257

Riedl CC, Slobod E, Jochelson M, Morrow M, Goldman DA, Gonen M, et al. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. J Nucl Med. 2014 Oct;55(10):1578-83

Sen F, Akpınar AT, Ogur U, Duman G, Tamgac F, Alper E. The impact of PET/CT imaging performed in the early postoperative period on the management of breast cancer patients. Nucl Med Commun. 2013 Jun;34(6):571-6

Ulaner GA, Castillo R, Goldman DA, Wills J, Riedl CC, Pinker-Domenig K, et al. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1937-44

Ulaner GA, Castillo R, Wills J, Gonen M, Goldman DA. 18F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer. Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1420-1427

Resources required

Koleva-Kolarova RG, Greuter MJ, van Kruchten M, Vermeulen KM, Feenstra T, Buskens E, et al. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients. Br J Cancer. 2015 May 12;112(10):1617-25